Fiscal Year Ending December 2026 Q3 Earnings Presentation Materials

Overview of Results

For the third quarter of the current fiscal year, consolidated net sales were 19,730 million yen (YoY increase of 31.6%) and operating income was 6,696 million yen (YoY increase of 57.9%). Pharmaceutical product sales reached 19,361 million yen and shipment volume was 41,596 tons, showing solid performance. Considering increased demand for core products such as CZ, V-Bond, and EXE along with foreign exchange effects, the company expects to raise its full-year forecast by the end of the fiscal year.

Outlook and Capital Investment

The full-year forecast for FY2026 is net sales of 26,500 million yen, operating income of 8,700 million yen, and net income of 6,100 million yen, representing an expected increase from the previous forecast. The company disclosed capital expenditure plans including commencement of the second phase of construction at the Kitakyushu plant with operations planned to start in fiscal 2028, and acquisition of land adjacent to the Nagaoka plant. Funding will be sourced from internal funds and borrowings, and the company will balance shareholder returns and growth investment in line with its cash allocation policy.